Models for VEGF-B induced physiological and pathological cardiac hypertrophy

被引：0
|
作者：
Rasanen, M. O. H. [1 ]
Hemanthakumar, K. Amudhala [1 ]
Paech, J. B. [1 ]
Robciuc, M. R. [1 ]
Ramanujam, D. [2 ]
Lahteenvuo, J. B. [3 ]
Engelhardt, S. [2 ]
Kivela, R. [1 ]
Alitalo, K. [1 ]
机构：
[1] Wihuri Res Inst, Helsinki, Finland
[2] Tech Univ Munich, Inst Pharmakol & Toxikol, Munich, Germany
[3] AI Virtanen Inst Mol Sci, Kuopio, Finland
来源：
CARDIOVASCULAR RESEARCH | 2018年 / 114卷
关键词：
D O I：
10.1093/cvr/cvy060.165
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
234
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [1] Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy
    Sultan, Ibrahim
    Ramste, Markus
    Peletier, Pim
    Hemanthakumar, Karthik Amudhala
    Ramanujam, Deepak
    Tirronen, Annakaisa
    von Wright, Ylva
    Antila, Salli
    Saharinen, Pipsa
    Eklund, Lauri
    Mervaala, Eero
    Yla-Herttuala, Seppo
    Engelhardt, Stefan
    Kivelae, Riikka
    Alitalo, Kari
    [J]. CIRCULATION RESEARCH, 2024, 134 (11) : 1465 - 1482
  • [2] Physiological and pathological cardiac hypertrophy
    Shimizu, Ippei
    Minamino, Tohru
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 97 : 245 - 262
  • [3] An investigation of hypertrophy-related genes in physiological and pathological models of cardiac hypertrophy
    Ferreira, L
    Harrison, G
    Headrick, JP
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 39 (03) : 575 - 575
  • [4] Nuclear translocalisation of VEGF-B and VEGFR-1 during cardiac hypertrophy and development
    Tirronen, A. K.
    Huusko, J.
    Dijkstra, M. H.
    Kaikkonen, M. U.
    Tavi, P.
    Yla-Herttuala, S.
    [J]. HUMAN GENE THERAPY, 2015, 26 (10) : A42 - A42
  • [5] VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
    Zhang, Fan
    Tang, Zhongshu
    Hou, Xu
    Lennartsson, Johan
    Li, Yang
    Koch, Alexander W.
    Scotney, Pierre
    Lee, Chunsik
    Arjunan, Pachiappan
    Dong, Lijin
    Kumar, Anil
    Rissanen, Tuomas T.
    Wang, Bin
    Nagai, Nobuo
    Fons, Pierre
    Fariss, Robert
    Zhang, Yongqing
    Wawrousek, Eric
    Tansey, Ginger
    Raber, James
    Fong, Guo-Hua
    Ding, Hao
    Greenberg, David A.
    Becker, Kevin G.
    Herbert, Jean-Marc
    Nash, Andrew
    Yla-Herttuala, Seppo
    Cao, Yihai
    Watts, Ryan J.
    Li, Xuri
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (15) : 6152 - 6157
  • [6] Mechanisms of physiological and pathological cardiac hypertrophy
    Nakamura, Michinari
    Sadoshima, Junichi
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (07) : 387 - 407
  • [7] Mechanisms of physiological and pathological cardiac hypertrophy
    Michinari Nakamura
    Junichi Sadoshima
    [J]. Nature Reviews Cardiology, 2018, 15 : 387 - 407
  • [8] Overexpression of VEGF-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy
    Bry, M.
    Karpanen, T.
    Ollila, H. M.
    Yla-Herttuala, S.
    Oresic, M.
    Alitalo, K.
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 : 277 - 277
  • [9] Comparative proteomic analysis of mouse models of pathological and physiological cardiac hypertrophy, with selection of biomarkers of pathological hypertrophy by integrative proteogenomics
    Kwon, Hye Kyeong
    Jeong, Hyobin
    Hwang, Daehee
    Park, Zee-Yong
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2018, 1866 (10): : 1043 - 1054
  • [10] Resveratrol prevents pathological but not physiological cardiac hypertrophy
    Vernon W. Dolinsky
    Carrie-Lynn M. Soltys
    Kyle J. Rogan
    Anita Y. M. Chan
    Jeevan Nagendran
    Shaohua Wang
    Jason R. B. Dyck
    [J]. Journal of Molecular Medicine, 2015, 93 : 413 - 425
12345